IDH1 and acute myeloid leukemia: The AGILE study, a phase 3 clinical trial, reported a significantly longer event-free survival when Ivosidenib was given in combination with AZA, relative to AZA monotherapy, in newly diagnosed IDH1-mutated AML patients that were ineligible for intensive chemotherapy induction [107].